GB001 in Adult Participants With Chronic Rhinosinusitis
Status:
Completed
Trial end date:
2020-08-05
Target enrollment:
Participant gender:
Summary
A Phase 2a, randomized, double-blind, placebo-controlled, multi-center study to evaluate the
efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of GB001 compared with
placebo over 16 weeks of treatment in patients with chronic rhinosinusitis with or without
nasal polyposis (NP).
Phase:
Phase 2
Details
Lead Sponsor:
GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc.